Q1 Earnings Forecast for TNXP Issued By Zacks Research

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) – Equities researchers at Zacks Research issued their Q1 2026 earnings per share estimates for shares of Tonix Pharmaceuticals in a note issued to investors on Monday, March 23rd. Zacks Research analyst D. Bautz expects that the company will post earnings of ($3.14) per share for the quarter. The consensus estimate for Tonix Pharmaceuticals’ current full-year earnings is ($1,762.50) per share. Zacks Research also issued estimates for Tonix Pharmaceuticals’ Q2 2026 earnings at ($2.75) EPS, Q3 2026 earnings at ($2.48) EPS, Q4 2026 earnings at ($2.32) EPS, FY2026 earnings at ($10.52) EPS and FY2027 earnings at ($3.70) EPS.

Other equities analysts also recently issued reports about the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Tonix Pharmaceuticals in a research report on Wednesday, January 21st. Wall Street Zen upgraded Tonix Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, January 17th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold”.

Tonix Pharmaceuticals Trading Down 2.2%

NASDAQ:TNXP opened at $15.00 on Thursday. The company has a market capitalization of $201.08 million, a P/E ratio of -1.05 and a beta of 1.88. Tonix Pharmaceuticals has a 12 month low of $13.07 and a 12 month high of $69.97. The firm has a fifty day simple moving average of $15.54 and a 200-day simple moving average of $18.14.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its quarterly earnings results on Thursday, March 12th. The company reported ($3.98) EPS for the quarter, missing analysts’ consensus estimates of ($3.16) by ($0.82). Tonix Pharmaceuticals had a negative net margin of 946.22% and a negative return on equity of 60.15%. The business had revenue of $5.39 million during the quarter, compared to analysts’ expectations of $2.97 million.

Institutional Investors Weigh In On Tonix Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in TNXP. Legal & General Group Plc purchased a new stake in shares of Tonix Pharmaceuticals in the second quarter valued at about $25,000. Ameritas Investment Partners Inc. acquired a new position in Tonix Pharmaceuticals in the 2nd quarter valued at about $28,000. Russell Investments Group Ltd. purchased a new stake in shares of Tonix Pharmaceuticals in the 3rd quarter valued at approximately $29,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Tonix Pharmaceuticals during the 2nd quarter worth approximately $62,000. Finally, State of Wyoming acquired a new stake in shares of Tonix Pharmaceuticals during the 4th quarter worth approximately $27,000. Institutional investors and hedge funds own 82.26% of the company’s stock.

Insider Activity

In related news, CEO Seth Lederman purchased 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 18th. The shares were purchased at an average price of $14.89 per share, with a total value of $223,350.00. Following the purchase, the chief executive officer owned 15,001 shares of the company’s stock, valued at $223,364.89. The trade was a 1,500,000.00% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.03% of the stock is owned by company insiders.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company’s pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.

Among Tonix’s lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD.